The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
The alliance will leverage Charleston, Veravas' sample prep technology and Tymora's extracellular vesicle enrichment technology.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.
The funding will be used to run a study of breath-based biomarkers and measures of small airway function to enable the definitive diagnosis of asthma.
KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
Astute is the maker of Nephrocheck, an immunoassay test for biomarkers predicting acute kidney injury.
The Codex4SMEs project, which has a €3.1 million budget, involves seven countries to increase cooperation in Europe's northwest region to develop companion diagnostics.
The LITMUS project will bring together clinicians and researchers from academia and pharma to develop, validate, and quantify better biomarkers for testing NAFLD.
The Swedish firm will use its CETSA technology to profile the effects of a drug on up to 6,000 proteins from patient blood samples.